Evidence map›Paper›PMID 38539463›Full record

ArticleCancers2024

Determination of the Prevalence of Microsatellite Instability,

Tomas Rendek, Rami Saade, Ondrej Pos, Georgina Kolnikova, Monika Urbanova, Jaroslav Budis, Luboslav Mihok, Miroslav Tomas, Tomas Szemes, Vanda Repiska

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Single-cell transcriptomic analysis reveals cellular heterogeneity and prognostic subtypes in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Tomas RendekInstitute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia.
Rami Saade2nd Department of Gynaecology and Obstetrics, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia.ORCID 0000-0001-9008-4866
Ondrej PosGeneton Ltd., 841 04 Bratislava, Slovakia.ORCID 0000-0003-2491-2285
Georgina KolnikovaDepartment of Pathological Anatomy, National Cancer Institute, 833 10 Bratislava, Slovakia.
Monika UrbanovaDepartment of Pathological Anatomy, National Cancer Institute, 833 10 Bratislava, Slovakia.
Jaroslav BudisGeneton Ltd., 841 04 Bratislava, Slovakia.ORCID 0000-0002-8667-6655
Luboslav MihokDepartment of Medical Genetics, National Cancer Institute, 833 10 Bratislava, Slovakia.
Miroslav TomasNational Cancer Institute, Surgical Oncology Clinic of Slovak Medical University, 833 10 Bratislava, Slovakia.ORCID 0000-0002-1114-5120
Tomas SzemesGeneton Ltd., 841 04 Bratislava, Slovakia.
Vanda RepiskaInstitute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia.
Comenius University Bratislava · SKGeneton (Slovakia) · SKSlovak Medical University · SK

Funding

USCCCORD 313021BUZ3
6 · The paper itself

Abstract

Slovakia has one of the highest rates of colorectal cancer among the developed countries, ranking as the second highest in the incidence of this disease for men worldwide. Despite the significant burden on both quality of life and the healthcare system this disease imposes, data on molecular analysis of biomarkers in CRC-diagnosed patients is scarce. In our study, we analyzed confirmed CRC patients from the database of the National Cancer Institute (NCI) and evaluated the presence of 4 biomarkers in tumor tissues. Altogether, 83 FFPE tumor tissues from CRC patients listed in the NCI database were analyzed for microsatellite instability status, presence of BRAF and KRAS/NRAS mutations, and neoplastic cell percentage in tissue samples. We identified 4 MSI-high samples, 39 KRAS/NRAS mutations, and 5 BRAF p.V600E mutations, with one case of coexistence of all three markers in a single tumor sample. We also evaluated possible relationships between biomarkers, their coexistence, and the age and sex of the studied population.

Indexed as

BRAFcolorectal cancerKRASmicrosatellite instabilityNRAS mutations

Identifiers

PMID38539463
PMCPMC10969032
OpenAlexW4392697055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.